Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
HAE 
Haemonetics Corporation (HAE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: HAE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $90.73
1 Year Target Price $90.73
| 3 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.9% | Avg. Invested days 42 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.55B USD | Price to earnings Ratio 22.3 | 1Y Target Price 90.73 |
Price to earnings Ratio 22.3 | 1Y Target Price 90.73 | ||
Volume (30-day avg) 10 | Beta 0.37 | 52 Weeks Range 55.30 - 94.98 | Updated Date 06/30/2025 |
52 Weeks Range 55.30 - 94.98 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 12.32% | Operating Margin (TTM) 17.2% |
Management Effectiveness
Return on Assets (TTM) 6.65% | Return on Equity (TTM) 18.83% |
Valuation
Trailing PE 22.3 | Forward PE 15.24 | Enterprise Value 4463467626 | Price to Sales(TTM) 2.61 |
Enterprise Value 4463467626 | Price to Sales(TTM) 2.61 | ||
Enterprise Value to Revenue 3.28 | Enterprise Value to EBITDA 13.23 | Shares Outstanding 48041200 | Shares Floating 47458150 |
Shares Outstanding 48041200 | Shares Floating 47458150 | ||
Percent Insiders 1.1 | Percent Institutions 118.5 |
Analyst Ratings
Rating 4 | Target Price 90.73 | Buy 5 | Strong Buy 3 |
Buy 5 | Strong Buy 3 | ||
Hold 1 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Haemonetics Corporation
Company Overview
History and Background
Haemonetics was founded in 1971. It is a global medical technology company focused on blood and plasma component collection, processing and analysis technologies.
Core Business Areas
- Plasma: Provides automated plasma collection technologies and solutions used by plasma fractionators.
- Blood Center: Offers solutions for blood collection, processing, and storage to blood centers.
- Hospital: Develops and markets products used in hospitals for blood management and cell salvage.
Leadership and Structure
Ronald E. Gelbman serves as President and Chief Executive Officer. The company has a board of directors and operates with a functional organizational structure.
Top Products and Market Share
Key Offerings
- NexSys PCS: Automated plasma collection system. Competitors include Terumo BCT (not publicly traded in US as entire company), Fresenius Kabi (not publicly traded in US) and Macopharma (not publicly traded in US).
- Cell Saver Elite+: Autotransfusion system for blood salvage during surgery. Competitors include LivaNova (LIVN) and Medtronic (MDT).
Market Dynamics
Industry Overview
The industry is characterized by increasing demand for blood and plasma products, technological advancements in collection and processing, and stringent regulatory requirements.
Positioning
Haemonetics holds a leading position in plasma collection and blood management solutions, driven by its technology and established relationships with plasma fractionators and blood centers.
Total Addressable Market (TAM)
The global blood and plasma products market is estimated to be hundreds of billions annually. Haemonetics is positioned to capitalize on the growing demand for its solutions within this market.
Upturn SWOT Analysis
Strengths
- Strong market position in plasma collection
- Innovative technology portfolio
- Established customer relationships
- Global presence
- High barriers to entry
Weaknesses
- Dependence on plasma market cycles
- Exposure to regulatory changes
- Limited product diversification
- Slower growth in some segments
Opportunities
- Expansion into emerging markets
- Development of new products and services
- Acquisitions to broaden portfolio
- Increasing demand for plasma-derived therapies
- Partnerships and collaborations
Threats
- Competition from established players
- Pricing pressure
- Technological disruptions
- Economic downturns
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- TER
- FMS
- LIVN
- MDT
Competitive Landscape
Haemonetics competes on product performance, innovation, and customer service. It has a strong position in plasma but faces competition from larger diversified medical device companies in other areas.
Major Acquisitions
Cardiva Medical, Inc.
- Year: 2021
- Acquisition Price (USD millions): 510
- Strategic Rationale: Expanded Haemonetics' portfolio into vascular closure systems, complementing its blood management solutions.
Growth Trajectory and Initiatives
Historical Growth: Historically, Haemonetics has grown through product innovation, strategic acquisitions, and market expansion.
Future Projections: Analyst estimates vary but generally project continued growth driven by demand for plasma and blood products.
Recent Initiatives: Recent initiatives include new product launches, expansion in emerging markets, and cost-saving measures.
Summary
Haemonetics is a financially stable company with a leading position in the plasma collection market. Its innovative technology and established customer base are strengths. It must navigate competition and regulatory changes while capitalizing on growth opportunities in emerging markets and expanding its product portfolio.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Haemonetics Investor Relations website
- SEC filings (10-K, 10-Q)
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data and analyst estimates are subject to change. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Haemonetics Corporation
Exchange NYSE | Headquaters Boston, MA, United States | ||
IPO Launch date 1991-05-09 | CEO, President & Director Mr. Christopher A. Simon | ||
Sector Healthcare | Industry Medical Devices | Full time employees 3023 | Website https://www.haemonetics.com |
Full time employees 3023 | Website https://www.haemonetics.com | ||
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.